PsO Pipeline Update: Icotrokinra, an Oral IL-23 Blocker, Looks Good in Topline Phase 3 Data

November 18, 2024

Johnson & Johnson Debuts Tremfya Clearance Photo Library

October 25, 2024

InnoCare’s TYK2 Performs Well in Phase II PsO Study

October 9, 2024

La La Anthony Partners With Amgen to Encourage Psoriasis Patients To Speak Up

October 4, 2024

Deucravacitinib (Sotyktu) Meets Main Goals in Phase 3b/4 Scalp PsO Study

September 27, 2024

Stress May Kickstart Psoriasis Flare-ups

September 27, 2024

Potential PsO Breakthrough: Exploring the Role of an Iron-regulating Hormone in the Etiology of Psoriasis

September 26, 2024

Pso Far, PsO Good: Bimekizumab (Bimzelx) Shows Long-term Efficacy in Psoriasis

September 25, 2024

One in Four Psoriasis Patients Show Signs of Psoriatic Arthritis

September 16, 2024

FDA Approves Alembic’s Generic Scalp Psoriasis Treatment

August 28, 2024

Biosimilar Update: EC Approves Stelara Biosimilar

August 26, 2024

Study: Obese Kids May Be More Likely to Develop AD, PsO, or AA

August 21, 2024